Osteopore Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Osteopore heeft een totaal eigen vermogen van A$1.8M en een totale schuld van A$1.1M, wat de schuld-eigenvermogensverhouding op 59.8% brengt. De totale activa en totale passiva bedragen respectievelijk A$4.5M en A$2.7M.

Belangrijke informatie

59.8%

Verhouding schuld/eigen vermogen

AU$1.08m

Schuld

Rente dekkingsratio	n/a
Contant	AU$2.28m
Aandelen	AU$1.80m
Totaal verplichtingen	AU$2.74m
Totaal activa	AU$4.55m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$3.7M ) OSX } overtreffen de korte termijn passiva ( A$2.7M ).

Langlopende schulden: De kortetermijnactiva OSX ( A$3.7M ) overtreffen de langetermijnschulden ( A$5.6K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: OSX heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van OSX is de afgelopen 5 jaar gestegen van 29.1% naar 59.8%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: OSX heeft voldoende cash runway voor 8 maanden op basis van de laatst gerapporteerde vrije kasstroom, maar heeft sindsdien extra kapitaal opgehaald.

Voorspelling contante baan: Er wordt voorspeld dat OSX voldoende kasmiddelen zal hebben voor 7 maanden op basis van de vrije kasstroom schattingen, maar heeft sindsdien extra kapitaal opgehaald.

Osteopore Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Osteopore Limited Appoints Yujing Lim as Executive Director

New major risk - Financial position

New major risk - Shareholder dilution

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 30, 2024

Less than half of directors are independent

Osteopore Limited has filed a Follow-on Equity Offering in the amount of AUD 2.99532 million.

Full year 2023 earnings released: AU$0.031 loss per share (vs AU$0.51 loss in FY 2022)

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Less than half of directors are independent

Less than half of directors are independent

Osteopore Limited Announces Resignation of Deborah Ho as Joint Company Secretary

First half 2023 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in 1H 2022)

Full year 2022 earnings released: AU$0.034 loss per share (vs AU$0.031 loss in FY 2021)

Osteopore Limited Enters Orthopaedic Market in Great Britain

Osteopore Limited Announces Appointment of Kellie Davis as Joint Company Secretary, Effective 26 January 2023

Less than half of directors are independent

Osteopore Limited (ASX:OSX) agreed to acquire Businesses Of Lomic Korea, 3D Aesthetic Solutions, 3D Healthcare Solutions And 3D Aesthetic Medical Lim Jae Hoon from Lim Jae Hoon for AUD2.05 million.

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings released: AU$0.017 loss per share (vs AU$0.012 loss in 1H 2021)

Insider recently bought AU$1.9m worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Osteopore Limited Announces Appointment of Dr. Lim Jing as Chief Operating Officer

Osteopore Limited, Annual General Meeting, May 31, 2022

Less than half of directors are independent

Osteopore Limited Announces Resignation of Vlado Bosanac as Non-Executive Director

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

Non Executive Chairman Brett Sandercock has left the company

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Osteopore Limited Announces A Cooperation Agreement with Terumo Blood and Cell Technologies

Osteopore International Collaborates with Maastricht University Medical Centre to Develop Implant Solution That Prevents Leg Amputations

Osteopore Limited Signs Distribution Agreement with MTG Medizintechnik Göhl

Osteopore Limited Announce the Appointment of Carl Runde as Chief Financial Officer

First half earnings released

Osteopore Limited has completed a Follow-on Equity Offering in the amount of AUD 8.5 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven